Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.84 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569965 | 1.00 | OPRK1 (0.84) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26308195 | 1.00 | OPRK1 (0.84) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL2638855 | 0.92 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL29425177 | 0.92 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL2638130 | 0.92 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL8055714 | 0.92 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| Aticaprant SCHEMBL29940327 | 0.92 | OPRK1 (1.00) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214372 | 0.83 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214364 | 0.83 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 | |
| SCHEMBL26214370 | 0.83 | OPRK1 (0.85) | OPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | claimed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | claimed |
| EP-4489748-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | ATIC, ADORA1, ADORA2A | OPRK1 1387/4885OPRM1 1523/4885OPRD1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.